Asunto(s)
Transfusión Sanguínea , Volumen Sanguíneo , Hemorragia/terapia , Sustitutos del Plasma/administración & dosificación , Enfermedad Aguda , Adolescente , Adulto , Anciano , Anticoagulantes/administración & dosificación , Pruebas de Coagulación Sanguínea , Cuidados Críticos , Dextranos/administración & dosificación , Femenino , Gelatina/administración & dosificación , Hemodinámica , Hemorragia/fisiopatología , Humanos , Derivados de Hidroxietil Almidón/administración & dosificación , Masculino , Persona de Mediana Edad , Succinatos/administración & dosificaciónRESUMEN
The paper presents the experience gained by a critical hematological care team in diagnosis and treatment of hemodilution coagulopathy. The investigations were performed in Leningrad obstetric hospitals in 1985-1990 and included 38 patients. Basic principles of the therapy and its control are described. The policy of infusion-transfusion treatment indicated in the paper secured successful management of puerpera with massive blood loss.
Asunto(s)
Trastornos de la Coagulación Sanguínea/terapia , Transfusión Sanguínea , Hemodilución/efectos adversos , Hemorragia Posparto/terapia , Adulto , Trastornos de la Coagulación Sanguínea/etiología , Femenino , Humanos , Infusiones Intravenosas , EmbarazoAsunto(s)
Hemodilución/efectos adversos , Hemorragia/terapia , Sustitutos del Plasma/efectos adversos , Trombocitopenia/etiología , Reacción a la Transfusión , Enfermedad Aguda , Adulto , Coloides , Terapia Combinada , Femenino , Hemorragia/sangre , Humanos , Masculino , Sustitutos del Plasma/administración & dosificación , Trombocitopenia/prevención & controlRESUMEN
The authors discuss the drawbacks of the graphic method for estimating the activities of the blood coagulation factors V, VII, and VIII and suggest a mathematical formula for calculation of these factors activities, appropriate coefficients, and a universal program for "Elektronika" B3-34, MK-54, and MK-56 microcalculators.
Asunto(s)
Factores de Coagulación Sanguínea/fisiología , Microcomputadores , Programas Informáticos , HumanosRESUMEN
The authors suggest that factor VIII activity be calculated relative to the value of activated partial thromboplastin time of substrate hemophilic plasma. This value is determined by replacing the tested plasma in the reaction mixture with veronal-acetate buffer. This modification has been developed to eliminate the shortcomings of the single-step technique for measuring this factor activity, that are explained by the use of nonstandard donor plasma and by the necessity to have such plasma during the investigation. A formula has been derived for the calculation of factor VIII coagulation activity in hemophilic patients and the advantages of the suggested modification are demonstrated.